Ignite Creation Date:
2025-12-25 @ 4:42 AM
Ignite Modification Date:
2025-12-26 @ 3:43 AM
Study NCT ID:
NCT04740918
Status:
TERMINATED
Last Update Posted:
2025-08-08
First Post:
2021-02-03
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
Sponsor:
Hoffmann-La Roche
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-06-07
Start Date Type:
ACTUAL
Primary Completion Date:
2024-06-19
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-06-19
Completion Date Type:
ACTUAL
First Submit Date:
2021-02-03
First Submit QC Date:
None
Study First Post Date:
2021-02-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-06-12
Results First Submit QC Date:
None
Results First Post Date:
2025-08-08
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-22
Last Update Post Date:
2025-08-08
Last Update Post Date Type:
ACTUAL